Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update

18 Mar 2026, 19:28 by Michael Walen · The Markets Daily

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,110,696 shares, an increase of 17.9% from the February 12th total of 942,054 shares. Based on an average daily trading volume, of 888,480 shares, the short-interest ratio is presently 1.3 days. Currently, 1.7% of the company’s shares are sold short. Currently, 1.7% of the company’s shares are sold short. Based on an average daily trading volume, of 888,480 shares, the short-interest ratio is presently 1.3 days.

Opus Genetics Price Performance

IRD traded down $0.15 during trading on Wednesday, reaching $4.65. The company had a trading volume of 693,286 shares, compared to its average volume of 1,001,426. The company has a market cap of $330.63 million, a P/E ratio of -5.66 and a beta of 0.45. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $5.30. The business’s fifty day moving average price is $3.30 and its 200 day moving average price is $2.39.

Insider Transactions at Opus Genetics

In related news, Director Cam Gallagher bought 83,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was bought at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the transaction, the director owned 83,000 shares of the company’s stock, valued at $163,510. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On Opus Genetics

Institutional investors have recently added to or reduced their stakes in the stock. Occudo Quantitative Strategies LP bought a new position in Opus Genetics during the 4th quarter worth about $25,000. Comerica Bank acquired a new stake in shares of Opus Genetics in the 1st quarter valued at about $29,000. Virtu Financial LLC bought a new stake in shares of Opus Genetics in the fourth quarter valued at about $34,000. Raymond James Financial Inc. lifted its holdings in shares of Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new position in shares of Opus Genetics during the fourth quarter worth about $40,000. 14.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. BTIG Research increased their price target on shares of Opus Genetics from $7.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Wedbush boosted their price objective on shares of Opus Genetics from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Brookline Capital Acquisition raised shares of Opus Genetics to a “strong-buy” rating in a research note on Monday, December 1st. Finally, B. Riley Financial initiated coverage on shares of Opus Genetics in a research report on Wednesday, December 10th. They set a “buy” rating and a $9.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Opus Genetics presently has an average rating of “Buy” and an average price target of $9.33.

Get Our Latest Stock Report on Opus Genetics

About Opus Genetics

(Get Free Report)